# A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)

> **NCT07681271** · PHASE2 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 100 (estimated)

## Conditions studied

- Papulopustular Rosacea

## Interventions

- **DRUG:** LOU064
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07681271
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-30
- **Primary completion:** 2027-12-07
- **Final completion:** 2027-12-07
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07681271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07681271, "A Phase 2 Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib (LOU064) in Adult Patients With Papulopustular Rosacea (PPR)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07681271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*